Antithrombotic efficacy of an oral low molecular weight heparin conjugated with deoxycholic asset on microsurgical anastomosis in rats.
BACKGROUND
Thrombogenic occlusion, at the anastomotic microvessels, contributed impaired blood flow to flap failure. The effect of an orally active low molecular weight heparin (LMWH) derivative conjugated with deoxycholic acid (DOCA) on the patency of anastomosis of the crushed rat artery was investigated, expecting its antithrombogenic effect.


METHODS
60 Femoral arteries of 30 rats, divided into three groups of 20 each, were reanastomosed. LMWH-DOCA conjugate was orally administered prior to and after operation for 5 consecutive days. On the sixth day of operation, the patency of the anastomosed artery was evaluated.


RESULTS
The patency of oral LMWH-DOCA (10 mg/kg) group was significantly enhanced from 15% to 45%, compared to non-treated control group. On the other hand, when the dosage of LMWH-DOCA was reduced to 1mg/kg, its efficacy on anastomosis was not as efficacious in terms of patency. The intima of crushed artery was impaired and thrombus formation was examined in the control group. In the drug treated group, the patency was only compromised by a thin layer of thrombus that covered the inner layer of the vessel without causing any damage to the internal elastic lamina.


CONCLUSIONS
The medication of oral LMWH-DOCA conjugate has been vetted in microvascular anastomosis of the crushed artery. LMWH-DOCA was potentially useful for improving the patency in compromised vessels after microsurgery.
Eom
Jin Sup
JS
Department of Plastic Surgery, Asan Medical Center, College of Medicine, University of Ulsan, Seoul 138-736, South Korea.
Koh
Kyung S
KS
Al-Hilal
Taslim A
TA
Park
Jin Woo
JW
Jeon
Ok Cheol
OC
Moon
Hyun Tae
HT
Byun
Youngro
Y
D000284:Administration, Oral; D000714:Anastomosis, Surgical; D000818:Animals; D001157:Arterial Occlusive Diseases / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D003840:Deoxycholic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004334:Drug Administration Schedule; D005263:Femoral Artery / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D005343:Fibrinolytic Agents / Q000008:administration & dosage*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000031:analogs & derivatives*; D008866:Microsurgery; D051381:Rats; D017207:Rats, Sprague-Dawley; D013927:Thrombosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D013997:Time Factors; D014654:Vascular Patency / Q000187:drug effects*; D014656:Vascular Surgical Procedures
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; C521279:LMWH-DOCA conjugate; D003840:Deoxycholic Acid